



## **MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract**

Lyon, France, July 6 2026, 6.00pm CET - [MaaT Pharma](#) (EURONEXT: MAAT - the “Company”), a clinical-stage biotechnology company and a leader in the development of **Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation**, presents the results of its Annual and Extraordinary General Meeting held on Tuesday, June 16, 2026 at 9:30 am CET at the Company's office and broadcasted live ([replay available here](#)). The Company also provides an update on the liquidity contract managed by Kepler Cheuvreux as of June 30<sup>th</sup>, 2026.

### **Annual and Extraordinary General Meeting**

The quorum reached by the shareholders present, representing, or voting remotely, was above 69.61% of voting shares.

Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 90%. The following resolutions were approved:

- Approval of the financial statements for fiscal year 2025;
- The renewal of the terms of office for current directors Mr. Jean-Marie Lefèvre, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Hervé Affagard, Mr. Jean Volatier, Seventure Partners and Bpifrance Investissement;
- The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2025 fiscal year - details of the votes on the said resolution is available on the Company's website [here](#);
- Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations.

Only one resolution was rejected:

- Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (29th resolution).

In accordance with the approval of resolutions 19 and 20, the Company also announced that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company's shares listed on Euronext Paris. Information on this contract is available in the [Company's Universal Registration Document](#) (French only).

The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution are available on the Company's website [www.maatpharma.com](http://www.maatpharma.com) in the Investors/ Shareholder Meetings' section.

### **Half-year liquidity contract statement**

Under the liquidity contract entered into between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30<sup>th</sup>, 2026:

- 45,618 shares
- € 66,564.56
  
- Number of executions on buy side on semester: 2,998
- Number of executions on sell side on semester: 2,808
- Traded volume on buy side on semester: 222,290 shares for € 1,297,309.11
- Traded volume on sell side on semester: 203,219 shares for € 1,268,496.55

As a reminder :

- the following resources appeared on the last half-year statement on 31 December 2025 on the liquidity account:

- 26,547 shares
- € 94,695.27
  
- Number of executions on buy side on semester: 2,120
- Number of executions on sell side on semester: 2,342
- Traded volume on buy side on semester: 74,642 shares for € 332,072.16
- Traded volume on sell side on semester: 83,855 shares for € 394,938.88

- the following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22<sup>nd</sup>, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>2,998</b>	<b>222,290</b>	<b>1,297,309.11</b>	<b>2,808</b>	<b>203,219</b>	<b>1,268,496.55</b>
01/02/2026	-	-	-	5	1,000	5,470.00
01/05/2026	34	2,900	15,747.00	33	2,200	12,210.00
01/06/2026	41	3,050	15,707.50	20	1,700	8,806.00
01/07/2026	8	601	3,161.26	62	4,950	26,878.50
01/08/2026	49	4,749	25,312.17	33	2,420	13,285.80
01/09/2026	3	300	1,527.00	1	100	520.00
01/12/2026	31	2,750	13,722.50	27	1,779	9,055.11
01/13/2026	16	1,200	5,976.00	15	1,030	5,191.20
01/14/2026	46	3,350	15,845.50	10	834	3,994.86
01/15/2026	10	684	3,180.60	77	5,787	28,066.95
01/16/2026	10	621	3,136.05	30	2,270	11,554.30
01/19/2026	33	2,479	12,295.84	20	1,575	7,843.50
01/20/2026	20	1,350	6,615.00	32	2,625	13,098.75
01/21/2026	19	1,466	7,403.30	28	2,200	11,308.00
01/22/2026	22	1,700	8,959.00	38	2,540	13,614.40
01/23/2026	39	2,416	13,167.20	51	3,700	20,387.00
01/26/2026	10	863	5,117.59	58	4,200	25,074.00
01/27/2026	28	1,737	10,526.22	54	4,600	29,946.00
01/28/2026	30	2,400	17,352.00	58	4,272	31,313.76
01/29/2026	43	3,300	25,476.00	43	3,436	27,247.48
01/30/2026	64	5,800	42,688.00	42	3,390	25,628.40
02/02/2026	32	2,610	18,296.10	57	4,010	29,072.50
02/03/2026	28	2,300	17,204.00	41	3,250	24,667.50
02/04/2026	49	3,650	27,046.50	29	2,150	16,447.50
02/05/2026	34	2,526	17,884.08	26	1,788	12,819.96
02/06/2026	34	2,124	14,783.04	15	810	5,751.00
02/09/2026	11	800	5,656.00	37	2,612	18,597.44
02/10/2026	21	1,600	11,456.00	40	3,000	21,720.00
02/11/2026	25	1,800	12,834.00	11	649	4,672.80
02/12/2026	19	1,150	8,176.50	24	2,051	14,726.18
02/13/2026	16	1,201	8,503.08	39	3,400	25,330.00
02/16/2026	65	4,322	32,069.24	46	3,600	27,324.00
02/17/2026	37	2,428	18,137.16	31	2,200	16,654.00
02/18/2026	30	2,150	15,888.50	32	2,400	18,048.00
02/19/2026	28	1,915	14,458.25	28	1,950	14,937.00
02/20/2026	32	2,485	18,538.10	14	800	6,096.00
02/23/2026	37	2,800	20,552.00	27	2,100	15,666.00
02/24/2026	28	1,513	10,923.86	31	2,203	16,125.96
02/25/2026	27	1,389	10,195.26	30	2,042	15,172.06
02/26/2026	24	2,100	15,267.00	23	1,443	10,577.19
02/27/2026	23	1,857	13,314.69	17	1,172	8,532.16
03/02/2026	41	2,890	20,201.10	33	2,286	16,230.60
03/03/2026	49	3,600	24,696.00	13	1,051	7,314.96
03/04/2026	46	3,453	22,548.09	53	4,299	29,061.24
03/05/2026	18	1,300	8,996.00	36	2,362	16,722.96
03/06/2026	28	2,100	14,301.00	20	1,500	10,335.00
03/09/2026	16	1,200	8,076.00	37	2,305	15,904.50
03/10/2026	1	100	716.00	14	821	5,993.30
03/11/2026	16	1,000	7,160.00	6	500	3,600.00
03/12/2026	33	2,200	15,400.00	17	1,003	7,151.39

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>2,998</b>	<b>222,290</b>	<b>1,297,309.11</b>	<b>2,808</b>	<b>203,219</b>	<b>1,268,496.55</b>
03/13/2026	24	1,425	9,932.25	30	2,030	14,331.80
03/16/2026	10	1,000	6,950.00	29	1,810	12,706.20
03/17/2026	22	1,400	9,772.00	27	1,490	10,504.50
03/18/2026	19	1,400	9,800.00	20	1,100	7,744.00
03/19/2026	17	1,089	7,579.44	41	2,667	18,962.37
03/20/2026	20	1,700	12,070.00	25	2,200	15,774.00
03/23/2026	29	2,500	17,750.00	43	3,603	26,049.69
03/24/2026	81	6,536	44,902.32	24	2,012	14,365.68
03/25/2026	13	1,000	6,750.00	22	1,556	10,596.36
03/26/2026	32	2,626	17,174.04	7	700	4,613.00
03/27/2026	26	2,074	13,315.08	26	1,701	11,056.50
03/30/2026	71	5,447	33,444.58	8	505	3,110.80
03/31/2026	70	5,704	31,200.88	2	200	1,132.00
04/01/2026	18	1,191	6,693.42	32	2,600	15,002.00
04/02/2026	34	1,509	8,465.49	13	900	5,139.00
04/07/2026	14	600	3,360.00	-	-	-
04/08/2026	1	100	590.00	41	2,558	15,168.94
04/09/2026	35	2,450	14,136.50	9	501	2,910.81
04/10/2026	17	1,100	6,292.00	15	800	4,624.00
04/13/2026	28	2,000	11,060.00	2	130	720.20
04/14/2026	5	273	1,526.07	47	2,470	13,980.20
04/15/2026	29	1,577	8,831.20	8	800	4,536.00
04/16/2026	21	1,150	6,371.00	23	930	5,189.40
04/17/2026	24	1,800	9,990.00	24	1,687	9,480.94
04/20/2026	15	1,100	6,028.00	10	610	3,361.10
04/21/2026	45	2,037	11,020.17	12	901	4,919.46
04/22/2026	34	1,863	10,171.98	24	1,973	10,890.96
04/23/2026	14	1,200	6,384.00	20	1,001	5,355.35
04/24/2026	2	200	1,058.00	10	515	2,801.60
04/27/2026	1	100	564.00	59	4,618	26,692.04
04/28/2026	28	1,620	9,347.40	14	1,100	6,435.00
04/29/2026	32	2,054	11,892.66	14	992	5,803.20
04/30/2026	10	654	3,793.20	20	1,608	9,406.80
05/04/2026	10	1,000	5,930.00	26	1,556	9,336.00
05/05/2026	12	1,100	6,468.00	25	2,200	13,134.00
05/06/2026	9	700	4,263.00	40	2,940	18,257.40
05/07/2026	-	-	-	43	3,160	20,919.20
05/08/2026	34	2,542	16,650.10	4	101	664.58
05/11/2026	-	-	-	27	2,000	13,640.00
05/12/2026	26	1,900	14,079.00	30	2,000	15,200.00
05/13/2026	37	2,261	16,369.64	20	1,700	12,444.00
05/14/2026	37	2,803	20,545.99	26	2,000	15,160.00
05/15/2026	32	1,986	14,239.62	19	1,400	10,108.00
05/18/2026	40	3,110	21,396.80	10	541	3,787.00
05/19/2026	28	2,000	13,460.00	23	1,261	8,587.41
05/20/2026	31	2,000	13,320.00	27	2,045	13,701.50
05/21/2026	67	6,430	17,361.00	-	-	-
05/22/2026	16	1,300	4,121.00	-	-	-
05/25/2026	25	1,600	5,104.00	-	-	-
05/26/2026	9	900	2,754.00	1	100	312.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>2,998</b>	<b>222,290</b>	<b>1,297,309.11</b>	<b>2,808</b>	<b>203,219</b>	<b>1,268,496.55</b>
05/27/2026	18	2,500	7,100.00	-	-	-
05/28/2026	7	700	1,890.00	-	-	-
05/29/2026	-	-	-	3	300	822.00
06/01/2026	3	300	894.00	16	1,300	3,913.00
06/02/2026	13	1,100	3,201.00	5	300	903.00
06/03/2026	6	600	1,746.00	6	600	1,776.00
06/04/2026	8	700	2,023.00	8	600	1,758.00
06/05/2026	22	1,400	4,046.00	12	800	2,360.00
06/08/2026	24	1,550	4,324.50	3	300	846.00
06/09/2026	12	800	2,232.00	20	809	2,273.29
06/10/2026	11	851	2,340.25	20	991	2,774.80
06/11/2026	9	799	2,253.18	13	1,200	3,420.00
06/12/2026	7	700	2,023.00	30	2,011	5,852.01
06/15/2026	18	1,500	4,380.00	10	889	2,640.33
06/16/2026	20	1,400	3,990.00	3	300	861.00
06/17/2026	5	300	858.00	10	507	1,460.16
06/18/2026	11	918	2,625.48	10	696	2,004.48
06/19/2026	14	1,082	3,062.06	4	201	572.85
06/22/2026	10	900	2,493.00	-	-	-
06/23/2026	11	800	2,200.00	7	500	1,385.00
06/24/2026	15	1,000	2,710.00	7	700	1,911.00
06/25/2026	19	1,600	4,320.00	2	200	542.00
06/26/2026	37	3,000	7,800.00	9	900	2,403.00
06/29/2026	21	1,823	4,557.50	8	579	1,464.87
06/30/2026	19	1,577	3,769.03	16	899	2,193.56

## About MaaT Pharma

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.

As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.



## Contacts

### MaaT Pharma – Investor Relations

Eric Soyer  
Chief Financial Officer  
+33 4 28 29 14 00  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

### MaaT Pharma – Media Relations

Pauline Richaud  
Head of Communications  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)